Recurrence of membranous nephropathy (MN) after kidney transplantation represents a distinct and challenging clinical scenario. This page outlines the evidence-based approach to managing recurrent MN in transplant recipients.
This protocol applies to kidney transplant recipients who develop recurrent membranous nephropathy in the allograft. The history of kidney transplantation is a defining feature of this population and shapes the therapeutic approach.
The initial step in managing recurrent MN in this setting centres on a conservative, antiproteinuric strategy — optimising non-immunosuppressive measures before considering further interventions. The full structured regimen, including the complete sequence of options, is available via the link below.
DOI: 10.1016/j.kint.2021.05.015
Patients with recurrent MN should be treated with maximal conservative, antiproteinuric therapy.
View source ↗